https://www.acousia.com/ 2026-07-08T15:21:54+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-to-present-data-for-acou085-at-aro-2022-midwinter-meeting-february-5-9/ 2022-01-26T13:04:17+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-to-receive-cta-for-first-in-man-clinical-study-of-acou085/ 2022-01-26T13:04:28+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-presenting-at-upcoming-drug-development-and-b2b-conferences/ 2022-01-26T13:04:41+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-strengthening-its-rd-management-team/ 2022-01-26T13:04:52+00:00 https://www.acousia.com/acousia-therapeutics-announces-eur-10-million-series-b-financing-to-advance-its-hearing-loss-portfolio/ 2022-01-26T13:05:14+00:00 https://www.acousia.com/acousia-therapeutics-receives-eur-2-5-million-to-develop-innovative-therapy-to-treat-and-prevent-sensorineural-hearing-loss/ 2022-01-28T12:15:25+00:00 https://www.acousia.com/first-patient-with-age-related-hearing-loss-treated-with-acou085/ 2022-05-05T09:51:53+00:00 https://www.acousia.com/presenting-first-in-class-hearing-loss-treatment-program-with-acou085-at-the-2nd-inner-ear-therapeutics-summit-in-boston/ 2022-05-11T16:25:25+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-to-present-data-for-lead-candidates-acou085-acou082-at-aro-2023-midwinter-meeting-feb-11-15/ 2022-11-24T10:15:47+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-completes-clinical-phase-1-study-with-its-small-molecule/ 2022-12-07T15:54:05+00:00 https://www.acousia.com/hearing-loss-company-acousia-therapeutics-to-present-key-learnings-and-data-from-lead-development-programs-at-us-and-european-meetings-in-august-and-september/ 2023-08-11T11:12:11+00:00 https://www.acousia.com/green-lighted-for-game-changing-phase-2-trial/ 2023-10-05T12:02:52+00:00 https://www.acousia.com/acousia-therapeutics-attracts-new-investor-on-its-path-to-make-hearing-loss-a-treatable-disease/ 2024-01-09T09:02:28+00:00 https://www.acousia.com/hearing-loss-company-acousia-announces-first-patient-enrolled-in-its-phase-2-prohear-study/ 2024-08-09T13:08:22+00:00 https://www.acousia.com/acousia-therapeutics-to-present-its-clinical-phase-2-prohear-study-on-hearing-loss-treatment-candidate-acou085-at-upcoming-conferences/ 2024-08-09T13:11:54+00:00 https://www.acousia.com/acousia-therapeutics-reaches-50-percent-patient-enrollment-milestone-in-phase2-prohear-study/ 2025-04-28T10:47:10+00:00 https://www.acousia.com/prohear-study-highlighted-as-study-of-the-month-by-german-society-of-urology/ 2025-07-06T13:57:34+00:00 https://www.acousia.com/completion-of-patient-enrollment-phase-2-prohear-study-evaluating-acou085-for-prevention-of-cisplatin-induced-ototoxicity/ 2026-01-05T11:58:29+00:00 https://www.acousia.com/promising-first-in-patient-results-for-acou085-inn-bimokalner-in-cisplatin-induced-ototoxicity/ 2026-06-11T15:22:19+00:00